Sargent Investment Group »

Bridgebio Pharma shares owned by Sargent Investment Group

Quarter-by-quarter ownership of Bridgebio Pharma (BBIO) shares owned by Sargent Investment Group from 13F filings

Historical chart of Sargent Investment Group investment in Bridgebio Pharma

Tip: Access up to 7 years of quarterly data

All positions including Bridgebio Pharma held by Sargent Investment Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bridgebio Pharma by Sargent Investment Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $213k 5.3k 40.37

More positions owned by Sargent Investment Group

Spdr Ser Tr Bloomberg 3-12 M (BILS)
Apple (AAPL)
Microsoft Corporation (MSFT)
First Tr Exchange Traded Nasdaq Cyb Etf (CIBR)
Cantaloupe (CTLP)
Universal Display Corporation (OLED)
Blackstone Group Inc Com Cl A (BX)
Carlyle Group (CG)
First Tr Exchange-traded Cap Strength Etf (FTCS)
Palantir Technologies Cl A (PLTR)
Spdr Ser Tr Prtflo S&p500 Gw (SPYG)
International Business Machines (IBM)
Iron Mountain (IRM)
Spdr Ser Tr Prtflo S&p500 Vl (SPYV)
Amazon (AMZN)

View all positions for Sargent Investment Group

Top funds holding Bridgebio Pharma

Kohlberg Kravis Roberts & Co
Viking Global Investors
Vanguard Group
Aisling Capital Management
Laurion Capital Management
Cormorant Asset Management
Goldman Sachs Group
Lord, Abbett & Co
Frazier Life Sciences Management
Alliancebernstein
Perceptive Advisors
Citigroup
Wellington Management Company
Hillhouse Capital Advisors
Norges Bank Investment Management

View all funds holding Bridgebio Pharma